Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251714 · ClinicalTrials.gov registry record · Phase 1
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
A Phase 1 study of Breast Cancer and Advanced Solid Tumor, sponsored by Treadwell Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 4
- Study locations
NCT05251714: Active Phase 1 study of Breast Cancer and Advanced Solid Tumor, sponsored by Treadwell Therapeutics.
NCT05251714 is a Phase 1 study of Breast Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Treadwell Therapeutics. The registered enrollment target is 44 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05251714, a Phase 1 study of Breast Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Treadwell Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.
Primary Outcome
The number of subjects who experience an adverse event that was possibly related to study drug as assessed by CTCAE v 5.0.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG CFI-402257
Study Locations (4)
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- START San Antonio - San Antonio
Utah
- START - Mountain Region - West Valley City
Virginia
- Virginia Cancer Specialist - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What the registry record for NCT05251714 still lists
NCT05251714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT05251714 reports a single indexed study location in Ohio, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT05251714 about?
NCT05251714 is a clinical study titled "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer". The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.
What is the current status of trial NCT05251714?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2022-05-27. Estimated completion is 2026-08.
What conditions does trial NCT05251714 study?
This clinical trial studies the following conditions: Breast Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT05251714?
The interventions under investigation include: Fulvestrant (DRUG), CFI-402257 (DRUG).
Who is sponsoring clinical trial NCT05251714?
This trial is sponsored by Treadwell Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05251714 being conducted?
This trial has 4 study locations across Ohio, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05251714's enrollment target sits among peer trials
44 852nd of 1224 higher than 371 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI